LINK TO FULL SHARE
Abstract
An nuna cewa yawan shan sukari yana taimakawa kai tsaye wajen ƙara nauyi, wanda hakan ke ba da gudummawa ga ci gaban annobar kiba a duk duniya. Abin sha'awa, an nuna cewa ƙaruwar shan sukari yana ƙara yawan dopamine a cikin ƙwayoyin halittar nucleus accumbens (NAc), a cikin hanyar lada ta mesolimbic na kwakwalwa kamar magungunan cin zarafi da yawa . Mun bayar da rahoton cewa varenicline, wani agonist mai karɓar acetylcholine na nicotinic (nAChR) wanda FDA ta amince da shi wanda ke daidaita dopamine a cikin hanyar lada ta mesolimbic na kwakwalwa, yana rage yawan shan sucrose sosai, musamman a cikin yanayin amfani na dogon lokaci. An lura da irin wannan sakamako tare da wasu magungunan nAChR, wato mecamylamine da cytisine. Bugu da ƙari, mun nuna cewa shan sucrose na dogon lokaci yana ƙara α4β2 * kuma yana rage α6β2* nAChRs a cikin ƙwayoyin halittar nucleus accumbens, wani yanki mai mahimmanci na kwakwalwa da ke da alaƙa da lada. Idan aka haɗa su, sakamakonmu ya nuna cewa magungunan nAChR kamar varenicline na iya wakiltar sabuwar dabarar magani don rage yawan shan sukari.
Ambato: Shariff M, Quik M, Holgate J, Morgan M, Patkar OL, Tam V, da sauransu (2016) Masu daidaita sinadarin Acetylcholine na Neuronal Nicotinic suna rage yawan shan sukari. PLoS ONE 11(3): e0150270. doi:10.1371/journal.pone.0150270
Edita: James Edgar McCutcheon, Jami'ar Leicester, ƘARSHEN KINGDOM
An karɓa: Satumba 30, 2015; An karɓa: Fabrairu 11, 2016; An buga: Maris 30, 2016
Hakkin mallaka: © 2016 Shariff et al. Wannan wani labari ne da aka rarraba a ƙarƙashin sharuɗɗan Lasisin Haƙƙin mallaka na Creative Commons , wanda ke ba da izinin amfani, rarrabawa, da sake bugawa ba tare da ƙuntatawa ba a kowace hanya, muddin an yaba wa marubucin asali da tushensa.
Samuwar Bayanai: Ana samun bayanai daga ma'ajiyar bayanai ta yanar gizo www.figshare.com tare da DOI mai aiki: 10.6084/m9.figshare.2068161.
Kuɗi: An ba da kuɗin waɗannan nazarin ta hanyar waɗannan masu zuwa: 1. Majalisar Bincike ta Ostiraliya - lambar tallafi ta FT1110884 (zuwa SEB), www.arc.gov.au ; 2. Majalisar Bincike ta Lafiya da Lafiya ta Ƙasa - lambar tallafi ta 1049427 (zuwa SEB), www.nhmrc.gov.au ; da kuma 3. Cibiyar Lafiya ta Ƙasa - lambar tallafi ta NS59910 (zuwa MQ), www.nih.gov.
Abubuwan da ke da alaƙa da gasa: Marubutan sun bayyana cewa babu wani abin da ke da alaƙa da gasa.
1. Gabatarwa
Yawan shan sukari yana da alaƙa da ɗaya daga cikin muhimman abubuwan da ke haifar da annobar kiba ta yanzu, wanda yanzu ya zama ruwan dare a duk duniya [ 1 , 2 ]. Hakika, shan binge sucrose ya nuna cewa yana ƙara yawan dopamine a cikin ƙwayoyin halittar nucleus (NAc) [ 3-6 ] , wani muhimmin siffa na magungunan cin zarafi [ 7-14 ]. Bugu da ƙari, shan sukari na ɗan lokaci yana haifar da ƙaruwa a cikin bayyanar masu karɓar dopamine D1 a cikin NAc , raguwar bayyanar masu karɓar D2 a cikin NAc da striatum [ 15-17 ] da kuma ƙaruwa a cikin mRNA mai karɓar dopamine D3 a cikin NAc da caudate-putamen. Ana lura da irin waɗannan canje - canje a martanin cocaine da morphine [ 18-24 ].
Bugu da ƙari, an lura da raguwar matakan enkephalin mRNA a cikin NAc[ 25 ] bayan shan sukari akai-akai [ 17 ], tare da irin wannan lura a martanin da aka bayar ga allurar morphine akai-akai [ 22 , 23 ] ko kuma a cikin mutane masu dogaro da cocaine [ 26 ]. A ƙarshe, yayin janyewa daga shan sucrose na yau da kullun, beraye suna nuna rashin daidaito a cikin dopamine da acetylcholine, watau matakan dopamine suna raguwa yayin da matakan acetylcholine ke ƙaruwa [ 27 ], kama da canje-canje da aka lura da magunguna da yawa na cin zarafi, gami da morphine, nicotine da barasa [ 28-30 ] . Wannan yana ƙara ƙarfafa bincike kan tsarin limbic a matsayin yiwuwar maƙasudin magani don rage yawan shan sukari.
Tsarin limbic tarin tsarin kwakwalwa ne da suka haɗa da NAc da yankin ventral tegmental (VTA) waɗanda ke bayyana yanayin motsin rai kamar tsammanin lada da kwarin gwiwa [ 31 ] . Dangane da shan sukari, an nuna cewa tsarin mesolimbic yana nuna martani mai ƙarfi ga alamun sucrose [ 32-34 ]. Hakika, nazarin dabbobi ya nuna cewa cin abinci mai daɗi na dogon lokaci na iya haifar da canje-canje a cikin hanyoyin lada na kwakwalwa, wanda ke nuna rashin daidaito a cikin tsarin lada na yau da kullun [ 35 , 36 ].
A matakin kwayoyin halitta, Acetylcholine (ACh) daga cikin ƙwayoyin halittar cholinergic na NAc yana ɗaurewa da masu karɓar acetylcholine na nicotinic neuronal (nAChR), kuma yana daidaita sakin dopamine (DA) da halayen da aka ƙarfafa [ 37 ]. Abin sha'awa, an nuna cewa sucrose, kodayake a kaikaice, yana shafar sakin DA a cikin NAc ta hanyar nAChRs [ 38 ], yana nuna cewa nAChRs manufa ce mai kyau don maganin magunguna.
Duk da cewa an gano nau'ikan nAChR da yawa a cikin tsarin limbic, gami da NAc, ba a san gano nau'ikan nAChR da ke da hannu wajen yin sulhu da kuma kula da shan sucrose ba. Varenicline, wani agonist mai zaman kansa a α4β2*, α6β2*, da α3β2*-nAChRs (*yana nuna kasancewar wasu ƙananan ƙungiyoyi a cikin hadaddun masu karɓa) da kuma cikakken agonist a nau'ikan α7 da α3β4* [ 39 , 40 ] yana rage sha'awar nicotine da alamun janyewa [ 41 ] da kuma rage shan barasa [ 42 ]. Varenicline yana nuna inganci don daina shan taba ta hanyar farko, yana haɓaka sakin DA a cikin NAc kuma na biyu, yana rage sakin DA da nicotine ke haifarwa ta hanyar toshe wurin ɗaure nAChR cikin gasa [ 43 , 44 ]. Ganin yadda acetylcholine ke shiga cikin sha'awar abinci, zai zama abin sha'awa a gwada ingancin varenicline wajen rage yawan shan sucrose. Bugu da ƙari, gwada wasu magungunan nAChR na iya taimakawa wajen gano yuwuwar ƙananan ƙwayoyin nAChR da ake niyya.
2. Kaya da matakai
Magunguna 2.1
An shirya kashi 5% (w/v) sucrose da kuma kashi 0.2% (w/v) na saccharin (Sigma, ST. Louis, Amurka) a cikin ruwan famfo na RO-tap. An sayi Varenicline (6,7,8,9-tetrahydro-6,10-methano-6 H pyrazino[2,3- h ][3]benzazepine tartrate), mecamylamine ( N ,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine hydrochloride), da (-)-cytisine ((1 R ,5 S )-1,2,3,4,5,6-hexahydro-1,5-methano-8 H -pyrido[1,2- a ][1,5]diazocin-8-one) daga Tocris (Bristol, UK).
Dabbobin 2.2 da Gidaje
-An shekaru 5 na Wan Wistar berayen (183g ± 14g) (ARC, WA, Ostiraliya), an ɗora keɓaɓɓe cikin matakan sau biyu na matakan Plexiglas. An yi amfani da berayen ga yanayin gidan mutum, kulawa, da kuma sake zagayowar hasken rana kwanaki 5 kafin a fara gwaje-gwajen. Dukkanin berayen an ajiye su a cikin wani yanayi mai canzawa na 12-h wanda aka sauya / haske mai duhu (fitilu a dakin 9 am) tare da damar da ba'a iyakance abinci ba (daidaitaccen bera) da ruwa. Tsarin gwaje-gwajen sun bi ka'idodin ARRIVE kuma kwamiti na ɗabi'a na Kwamitin Ka'idodin Dabbobin Dabbobi na Jami'ar Queensland da Kwamitin Ka'idodin Dabbobin Universityaimala na Jami'ar Queensland, daidai da dokokin Turai (Kwamitin Kula da Al'ummomin Turai na 24 Nuwamba 1986, 86 / 609 / EEC).
2.3 Intermittent-samun damar zaɓi mai kwalban sha biyu
An daidaita tsarin shan ruwan kwalba biyu na 5% na sucrose ta hanyar amfani da lokaci-lokaci daga [ 45 ]. An gabatar da dukkan ruwaye a cikin kwalaben filastik masu digiri 300-ml tare da maɓuɓɓugan ruwan sha na bakin ƙarfe da aka saka ta cikin grommets biyu a gaban kejin bayan fara zagayowar hasken duhu. An gabatar da kwalaben biyu a lokaci guda: kwalba ɗaya da ke ɗauke da ruwa; kwalba ta biyu da ke ɗauke da 5% (w/v) sucrose. An canza wurin da aka sanya kwalban sucrose na 5% (w/v) tare da kowane fallasa ga sarrafawa don abubuwan da ake so. An auna kwalaben na tsawon minti 30, awanni 2, da awanni 24 bayan an gabatar da ruwan, kuma an ɗauki ma'auni zuwa 0.1gram mafi kusa. An kuma auna nauyin kowane bera don ƙididdige gram na shan sucrose a kowace kilogiram na nauyin jiki. A ranar Litinin bayan ƙarshen lokacin daidaitawa, an bai wa beraye (183 ± 14 g, n = 10-12) damar samun kwalba ɗaya na 5% (w/v) sucrose da kwalban ruwa ɗaya. Bayan awanni 24, an maye gurbin kwalbar sucrose da kwalbar ruwa ta biyu wacce take samuwa na tsawon awanni 24 masu zuwa. An maimaita wannan tsari a ranakun Laraba da Juma'a; Duk sauran kwanakin, berayen suna da damar samun ruwa ba tare da iyaka ba. An fara shan magani bayan berayen sun ci gaba da daidaita matakan shan ruwa na asali (20 ± 5 g/kg) na maganin sucrose na 5% (w/v) don (a) shan ruwa na ɗan gajeren lokaci [~ makonni 4 (zaman shan ruwa 13)]; da kuma, (b) shan ruwa na dogon lokaci [~ makonni 12 (zaman shan ruwa 37)]. Matsakaicin nauyin jiki a farkon gwajin magunguna shine 373 ± 26g na ɗan gajeren lokaci, da kuma 550 ± 48 g na dogon lokaci. An ba da magungunan nAChR, masu adawa da su, da abin hawa kamar yadda aka bayyana.
Don kwatanta bashin nasara na amfani da dabba a cikin dabbobi ta amfani da yarjejeniya na samun shiga tsakanin ta hanyar ci gaba da yarjejeniya ta samun dama, wata kungiya ta daban (n = 10) ta 5-mako tsohuwar wistar an kiyaye ta akan ci gaba da samun damar amfani da 5% sucrose yarjejeniya don 4 makonni. An bai wa waɗannan berayen damar yin amfani da kwalba guda na 5% sucrose da kuma kwalban ruwa guda 24 a rana, kwana bakwai a mako don tsawon lokacin gwajin. An sha nauyin Sucrose da kwalaban ruwa yau da kullun (jimlar zaman 56 tare da kwalabe waɗanda aka auna) don ƙididdige abincin da ya fi dacewa da kuma zaɓi. Hakanan an kuma yin awo da na dabbobi. An jera jigon kwalban na sucrose kowace rana don sarrafawa don zaɓin ɓangarorin.
Bugu da ƙari, don sanin tasirin varenicline akan amfani da mai daɗin abin maye, mai saccharin 0.2% (w / v), an gabatar dashi ga rukuni daban na berayen (n = 10) kamar yadda yake a cikin yarjejeniya samun damar shiga ta yadda aka bayyana. Makonni na 4 daga farkon cinikin saccharin, ana gudanar da berayen varenicline ta amfani da murabba'in latin a allurai kamar yadda aka bayyana. Aƙarshe, wani rukuni daban na beraye akan yarjejeniya ta hanyar shiga taɗi da keɓaɓɓe wanda aka tsara don autoradiography an kashe shi ta hanyar lalacewa kuma an cire kwakwalwar da sauri, daskararre cikin isopentane a kan kankara bushe kuma aka adana a -80 ° C. Sannan an raba kwakwalwar (8 μm) a matakin matakin amfani da cryostat (Leica Microsystems Inc., Deerfield, IL) wanda aka saita a -15 zuwa -20 ° C. Yankunan sun narke a jikin shimfidar rufin poly-L-lysine, bushe da adana su a -80 ° C har sai an yi amfani da autoradiography. Ratsin da ake cinye ruwa (watau babu sucrose) anyi amfani dashi azaman sarrafawa.
Jadawalin jiyya na 2.4
An raba berayen Wistar zuwa ƙungiyoyi 10-12. Ga berayen da suka sha giya na ɗan gajeren lokaci da kuma waɗanda suka sha giya na dogon lokaci, an ba wa kowace dabba Varenicline (abin hawa, 0.3, 1 da 2 mg/kg) ta amfani da tsarin murabba'in Latin. Bugu da ƙari, a cikin rukunin berayen (n = 8), an rubuta yawan abincin da aka ci bayan an ba wa varenicline zuwa gram 0.1 mafi kusa a kowane lokaci. Daga baya, bayan an koma shan giya na farko, an ba wa mecamylamine (abin hawa, 0.5, 1 da 2 mg/kg), kamar yadda aka yi a da. A cikin rukunin berayen daban, an ba wa (-)-cytisine (abin hawa, 2 da 4 mg/kg) ta amfani da tsarin murabba'in Latin. A ƙarshe, an ba wa wani rukunin bera daban da ke shan saccharin na ɗan gajeren lokaci varenicline kamar yadda aka yi a da. Kamar yadda aka tsara murabba'in Latin, kowane bera ya yi aiki a matsayin ikonsa. Allunan da aka yi amfani da su a cikin wannan binciken sun nuna waɗanda aka yi amfani da su a cikin wallafe-wallafen da ke akwai [ 46-51 ].
Dukkanin kwayoyi sun warwatse a cikin ruwan gishiri kuma ana gudanar dasu azaman allurar subcutaneous (sc), cikin girman 1 ml / kg, 30 min kafin a gabatar da nasara da kwalaban ruwa. Dukkanin hanyoyin magance magunguna an shirya su kai tsaye kafin kowane allurar.
2.5 125I-Epibatidine Autoradiography
An yi haɗin I-epibatidine 125 (2200 Ci/mmol; Perkin Elmer Life Sciences, Boston, MA, Amurka) kamar yadda aka ruwaito a baya [ 52 ]. An riga an saka zane-zanen a zafin jiki na 22°C na tsawon minti 15 a cikin buffer wanda ke ɗauke da 50 mM Tris, pH 7.5, 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl 2 , da 1.0 mM MgCl 2. An saka su na tsawon minti 40 tare da 0.015 nM 125 I-epibatidine a gaban ko babu α-conotoxin MII (α-CtxMII) (100 nM). Sannan aka wanke su, aka busar da su, sannan aka fallasa su ga Kodak MR Film tare da ma'aunin I-microscale 125 (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) na tsawon kwanaki 5-7. An tantance ɗaurewar da ba ta da takamaiman takamaiman abu a gaban nicotine 100 μM kuma yayi kama da fim ɗin da ba a saka ba.
2.6 mai ɗaukar hoto autoradiography
An auna ɗaurewa ga mai jigilar dopamine (DAT) ta amfani da 125 I-RTI-121 (2200 Ci/mmol; Perkin Elmer Life Sciences, Boston, MA, Amurka), kamar yadda aka bayyana a baya [ 53 ]. An riga an narke sassan da aka riga aka saka sau biyu na minti 15 kowannensu a 22°C a cikin 50 mM Tris-HCl, pH 7.4, 120 mM NaCl, da 5 mM KCl, sannan aka saka na tsawon awanni 2 a cikin buffer tare da albumin na jini na shanu 0.025%, fluoxetine 1 μM, da 50 pM 125 I-RTI-121. An yi amfani da Fluoxetine don toshe ɗaurewa da ba a yi niyya ba ga masu jigilar serotonin. An wanke sassan a 0°C na minti 4 × 15 kowanne a cikin buffer kuma sau ɗaya a cikin ruwan sanyi mai sanyi, an busar da su da iska, sannan aka fallasa su ga fim ɗin Kodak MR na tsawon kwana 2 tare da ƙa'idodin I-microscale 125 (GE Healthcare). An yi amfani da Nomifensine (100 μM) don bayyana alaƙar da ba ta da takamaiman takamaiman abu.
Nazarin Bayanai na 2.7
An yi amfani da shirin ImageQuant daga GE Healthcare don tantance ƙimar yawan gani daga fina-finan autoradiographic. An cire ƙimar nama daga jimillar haɗin nama don kimanta takamaiman haɗin nama na radioligands. Daga nan aka canza takamaiman ƙimar ɗaure zuwa nama na fmol/mg ta amfani da lanƙwasa na yau da kullun da aka ƙayyade daga ma'aunin I 125. An yi taka tsantsan don tabbatar da cewa karatun yawan gani na samfurin yana cikin kewayon layi.
Dukkanin ƙididdiga da daidaitattun abubuwa an gudanar dasu ta amfani da GraphPad Prism 6 (Graph Pad Software Co., San Diego, CA, Amurka). An yi kwatancen na ƙididdiga ta amfani da gwaje gwaje gwaje gwaje gwaje na gwaji, hanyar tantance banbanci (ANOVA) wanda ya biyo bayan Newman-Keuls na gwajin kwatancen da yawa ko ANOVA na biye da gwajin posting na Bonferroni. An yi la'akari da darajar p ≤0.05 mai mahimmanci. An bayyana duk dabi'un a matsayin ma'anar ± SEM na adadin dabbobi da aka nuna, tare da ƙaddamar da martaba ga kowane dabba wanda ke wakiltar matsakaiciyar alamun siginar 6 – 15 daga yanka 1 – 2.
3. Sakamako
3.1 Varenicline yana rage yawan amfani da sucrose ta amfani da tsaka-tsakin hanyar zaɓi biyu na kwalban
Domin bincika tasirin varenicline a cikin berayen da ke shan sucrose na ɗan gajeren lokaci (mako 4) da na dogon lokaci (mako 12), mun yi amfani da tsarin shan giya mai zaɓin kwalba biyu na ɗan lokaci [ 54 ]. Shan varenicline na ƙarƙashin fata (sc) a cikin berayen da ke shan sucrose na ɗan gajeren lokaci ( Hoto na 1A ) ya rage shan sucrose [ F (3, 33) = 3.8, P < 0.05]. Binciken bayan hoc ya nuna cewa 2 mg/kg kawai ya rage yawan shan sucrose sosai. Sabanin haka, a cikin berayen da ke shan sucrose na dogon lokaci ( Hoto na 1B ), yayin da varenicline ya rage yawan shan sucrose [ F (3, 24) = 15.24, P < 0.0001], binciken bayan hoc ya nuna cewa 1 da 2 mg/kg sun ragu sosai yawan shan sucrose ta hanyar da ta dogara da kashi idan aka kwatanta da abin hawa. Hakanan, varenicline na tsarin bai shafi shan chow a kowane lokaci da aka gwada da duk allurai masu tasiri ba, duka na ɗan gajeren lokaci da na dogon lokaci. Abin sha'awa, shan maganin varenicline a cikin berayen da ke cin saccharin na ɗan gajeren lokaci (makonni 4) ( Hoto na 1C ) ya rage shan saccharin [ F (3, 24) = 5.67, P < 0.05]. Binciken bayan hoc ya nuna cewa 2 mg/kg kawai ya rage yawan shan saccharin sosai. A duk lamuran da ke sama, an lura da mahimmanci a lokacin mintuna 30, ba tare da wani mahimmanci a lokacin awanni 2 da awanni 24 ba.
Varenicline (2 mg/kg) ya rage yawan shan sucrose sosai (Hoto na 1A) bayan shan sucrose na ɗan gajeren lokaci (makonni 4). Yayin da, duka (1 da 2 mg/kg na varenicline ya rage yawan shan sucrose sosai (Hoto na 1B ) bayan shan sucrose na dogon lokaci (makonni 12). Varenicline (2 mg/kg) ya rage yawan shan saccharin sosai (Hoto na 1C) bayan shan saccharin na ɗan gajeren lokaci (makonni 4). An bayyana ƙimar a matsayin matsakaicin shan sucrose (g/kg) ± SEM (ma'aunin da aka maimaita ANOVA sannan gwajin Newman—Keuls bayan hoc). *, P < 0.05; **, P < 0.01 idan aka kwatanta da abin hawa, n = 10–12.
Bugu da ƙari, sabanin tasirin varenicline akan shan sucrose da saccharin a cikin dabbobin da ke shan sucrose na ɗan gajeren lokaci (makonni 4) akan tsarin samun sucrose na ɗan gajeren lokaci, varenicline bai rage yawan shan sucrose a cikin dabbobi ba akan ci gaba da samun sucrose na ɗan gajeren lokaci (makonni 4) (Ba a nuna bayanai ba). Ya kamata a lura cewa beraye da ke shan lokacin da suka sha lokaci sun cinye sucrose sosai a cikin mintuna 30 na farko na gabatarwar kwalba fiye da beraye da ke shan lokacin da suka sha lokaci kamar yadda aka ƙaddara ta gwajin t-test mara haɗin kai mai wutsiya biyu (t = 4.025, df = 13, P < 0.01). Saboda haka, duk ƙarin gwaje-gwaje a cikin wannan binciken sun yi amfani da tsarin samun lokaci lokaci. A duk lokuta, shan ruwa bai shafi ba.
3.2 Mecamylamine, mai gwagwarmaya, mara kyau mai zaɓi na NAChR antagonist yana rage amfani da sucrose ta amfani da hanyar zaɓaɓɓiyar kwalba biyu
Mun sake duba tasirin mecamylamine, wani mai adawa da nAChR wanda ba shi da gasa, wanda ba shi da zaɓe, akan shan sucrose a cikin tsarin zaɓin kwalba biyu na lokaci-lokaci kamar yadda aka bayyana a sama. Mecamylamine ya rage yawan shan sucrose a cikin ɗan gajeren lokaci [ F (3, 33) = 5.9, P < 0.01 minti 30; F (3, 33) = 10.91, P <0.001 awa 2] da beraye masu cin sucrose na dogon lokaci [ F (3, 21) = 4.6, P < 0.05 minti 30; F (3, 21) = 10.42, P <0.001 awa 2]. Binciken bayan hoc ya nuna cewa kashi 2 mg/kg ya rage yawan shan sucrose sosai a cikin mintuna 30 a cikin ɗan gajeren lokaci ( Hoto na 2A ) da beraye masu cin sucrose na dogon lokaci ( Hoto na 2B ), da kuma a lokacin awanni 2. Haka kuma, 1 mg/kg ya kasance mai mahimmanci a cikin ɗan gajeren lokaci a lokacin awanni 2. Shan sucrose bai shafi lokacin awanni 24 na allurar da aka gwada ba. Yawan shan ruwa bai shafi lokaci da kuma yawan shan ba.
Mecamylamine (2 mg/kg) ya rage yawan shan sucrose sosai a cikin ɗan gajeren lokaci (makonni 4) da kuma beraye masu fallasa sucrose na dogon lokaci (makonni 12) (Hoto na 2A da 2B). An bayyana ƙimar a matsayin matsakaicin shan sucrose (g/kg) ± SEM (ma'aunin da aka maimaita ANOVA sannan gwajin Newman—Keuls bayan hoc ya biyo baya). *, P < 0.05; **, P < 0.01; ***, P < 0.001 idan aka kwatanta da abin hawa, n = 12.
3.3 Cytisine yana rage amfani da sucrose ta amfani da tsaka-tsakin hanyar zaɓi biyu na kwalban
An gwada rukuni na biyu na beraye da (-)-cytisine, wani mai maganin nAChR mai zaɓin β2. Cytisine ya rage yawan shan sucrose sosai a cikin ɗan gajeren lokaci [ F (2, 22) = 7.18, P < 0.01 minti 30; F (2, 22) = 6.82, P <0.01 awa 2] da beraye masu cin sucrose na dogon lokaci [ F (2,20) = 19.43, P < 0.0001 minti 30; F (2,20) = 12.94, P < 0.001 awa 2). Binciken bayan hoc ya nuna cewa yawan shan sucrose na 4 mg/kg ya ragu sosai a lokacin mintuna 30 a cikin ɗan gajeren lokaci ( Hoto na 3A ) da beraye masu cin sucrose na dogon lokaci ( Hoto na 3B ), da kuma a lokacin awanni 2. Yawan shan sucrose bai shafi lokacin awanni 24 na allurai da aka gwada ba. Haka kuma, shan ruwa bai shafi a kowane lokaci da kuma yawan da ake buƙata ba.
Cytisine (4 mg/kg) ya rage yawan shan sucrose sosai (Hoto na 3A da 3B) bayan fara shan giya a cikin ɗan gajeren lokaci (makonni 4) da kuma beraye masu fallasa sucrose na dogon lokaci (makonni 12). An bayyana ƙimar a matsayin matsakaicin shan sucrose (g/kg) ± SEM (ma'aunin da aka maimaita ANOVA sannan gwajin Newman—Keuls bayan hoc ya biyo baya). *, P < 0.05; **, P < 0.01; ***, P < 0.001 idan aka kwatanta da abin hawa, n = 12.
Nunawar 3.4 zuwa ga ɗan gajeren lokaci (mako na 4) da kuma dogon lokacin (sati na 12) nasarar amfani da NUM4β2 * kuma yana rage α6β2 * nAChR madaidaiciya madaidaiciya a cikin abubuwan haɗin nucleus
Tsarin ya ƙunshi manyan ƙungiyoyin nAChR guda biyu, nau'ikan α4β2* da α6β2* [ 55 ]. Domin tantance yadda maganin sucrose na dogon lokaci ya canza α4β2* da α6β2* da aka daidaita a cikin kwakwalwa, mun auna ɗaurewar I-epibatidine 125 a cikin rashin da kasancewar α-CtxMII, wanda ke toshe α6β2* nAChRs ( Hoto na 4A da 4B ). Haɗawa da aka ƙayyade a gaban α-CtxMII yana wakiltar abin da ke faruwa a α4β2* nAChRs, yayin da bambanci tsakanin jimillar da ɗaurewar α4β2* nAChR an ayyana shi azaman ɗaurewar α6β2* nAChR. An ƙara yawan nAChRs na α4(marasa α6)β2* a cikin NAc na dabbobin da aka yi wa maganin sucrose na ɗan gajeren lokaci da na dogon lokaci (gwajin T mara haɗin kai; p = 0.024 da <0.0001, bi da bi). Sabanin haka, an rage yawan α6β2* nAChRs ( Hoto na 4C da 4D ) sosai a cikin ɗan gajeren lokaci (gwajin t-ba tare da haɗin gwiwa ba; p = 0.028) da kuma na dogon lokaci (gwajin t-ba tare da haɗin gwiwa ba; p = 0.0035) tare da maganin sucrose. A ƙarshe, mun kuma kwatanta ɗaurewar mai jigilar dopamine (DAT) ta hanyar ɗaurewar I-RTI-121 125 don tantance daidaitawar shuttling na dopamine a cikin berayen da aka yi wa sucrose. Babu wani babban canji da aka lura na ɗan gajeren lokaci (mako 4) da na dogon lokaci (mako 12) (gwajin T-ba tare da haɗin gwiwa ba; p = 0.290 da 0.263, bi da bi).
Binciken ƙididdiga na ɗaurewar α4(nonα6)β2* nAChR ta amfani da ɗaurewar I-Epibatidine 125 a cikin rashin da kuma kasancewar α-CtxMII ya nuna ƙaruwa mai yawa a cikin α4(nonα6)β2* nAChRs (A da B) tare da raguwar fallasawar α6β2* nAChRs (C da D) bayan ɗan gajeren lokaci (mako 4) da kuma dogon lokaci (mako 12) na sucrose a cikin yanayin zaɓin kwalba biyu na lokaci-lokaci. Mai jigilar Dopamine (DAT) kamar yadda aka ƙaddara ta hanyar ɗaurewar I-RTI-121 ba ya nuna wani babban canji na ɗan gajeren lokaci (mako 4) da na dogon lokaci (mako 12) (E da F bi da bi). Kowane ƙima yana wakiltar matsakaicin _ SEM na dabbobi huɗu a kowace ƙungiya. Muhimmancin bambanci daga berayen da aka yi wa magani da abin hawa, ****p<0.0001, **p < 0.01, *p < 0.05.
4. Tattaunawa
Wannan binciken ya nuna cewa gudanar da varenicline ta hanyar tsari ya haifar da raguwar yawan shan sucrose ta hanyar amfani da tsarin zaɓin kwalba biyu na lokaci-lokaci , musamman bayan shan sucrose na dogon lokaci. An san cewa varenicline, wani agonist mai zaman kansa a neuronal α4β2*, α6β2*, da α3β2*-nAChRs da kuma cikakken agonist a nau'ikan α7 da α3β4* nAChR [ 39 , 40 ], yana rage sha'awar nicotine da alamun janyewa [ 41 ], haka kuma yana rage yawan shan ethanol a cikin nazarin dabbobi [ 42 ]. Bugu da ƙari, an nuna cewa varenicline yana daidaita tasirinsa a matakin NAc [ 56 ], wani muhimmin yanki na hanyar lada ta limbic a cikin kwakwalwa. An riga an nuna cewa ciyarwa zuwa ga ƙoshi yana ƙara ACh a cikin accumbens [ 57 ], musamman a cikin mahallin amfani da sucrose [ 58 ]. Abin sha'awa, rashin daidaito tsakanin dopamine (DA) da acetylcholine (ACh) a cikin tsarin limbic, musamman a cikin NAc ne aka gano yana haifar da kuma kiyaye halaye waɗanda ke ci gaba da jaraba ga abubuwan da ake amfani da su [ 59 , 60 ]. Abin sha'awa, varenicline bai shafi shan sucrose ba a cikin tsarin zaɓin kwalba biyu na ɗan gajeren lokaci wanda ke nuna cewa samun damar shiga cikin sucrose na iya taimakawa ga canje-canjen jijiyoyi wanda varenicline ke da tasiri. Duk da haka, nazarin gaba zai zama dole don tabbatar da wannan. Bugu da ƙari, yana da ban sha'awa musamman cewa varenicline ya rage ba kawai sucrose ba har ma da shan saccharin ba tare da shafar shan ruwa ba, yana nuna cewa abinci mai daɗi yana da mahimmanci, musamman dangane da yuwuwar shigar tsarin limbic. Bugu da ƙari, bayan tsawon lokaci (makonni 12) da aka fallasa ga sucrose, ƙaramin kashi na varenicline ya yi tasiri wajen rage yawan amfani da sucrose kamar yadda babban kashi yake. Wannan martanin daban-daban za a iya danganta shi da canje-canjen da aka lura a cikin ɗaurewa ga ƙananan sassan α4β2 waɗanda ke ɗauke da nAChR kamar yadda aka nuna a cikin wannan binciken.
Mun kuma lura cewa mecamylamine, wani mai adawa da nAChR wanda ba shi da zaɓe ba wanda ba shi da gasa ya rage yawan shan sucrose. Bincikenmu ya samu goyon bayan wani bincike da aka yi kwanan nan wanda ya gano cewa mecamylamine ya rage kwarin gwiwar Pavlovian don sukari r [ 61 ] da kuma sarrafa kansa, duk da cewa a cikin allurai mafi girma [ 62 ]. Bugu da ƙari, amfani da mecamylamine a cikin in vitro a cikin NAc, ya rage sakin DA accumbal na ghrelin [ 63 ]. Cytisine, mai adawa da nAChR na β2, wanda aka tallata a matsayin taimakon daina shan taba Tabex a ƙasashen gabashin Turai, shi ma ya rage yawan shan sucrose. Wani rahoto da ya gabata, duk da haka, yana binciken tasirin cytisine akan shan ethanol ya kammala da cewa cytisine (3 mg/kg, sc) bai rage yawan shan sucrose na son rai ba [ 64 ]. Baya ga bambance-bambancen nau'ikan da za a iya samu [ 65 ], akwai bambance-bambancen tsari da yawa tsakanin gwaje-gwajenmu da waɗanda Sajja da Rahman suka ruwaito (2011). Mafi mahimmanci, Sajja da Rahman (2011) sun yi amfani da ƙaramin allurai mafi girma (3 mg/kg) idan aka kwatanta da 4 mg/kg a cikin bincikenmu. Duk da haka, ko waɗannan abubuwan na iya kasancewa saboda bambance-bambancen da aka lura ba a san su ba a halin yanzu.
Bugu da ƙari, ya kamata a lura cewa tasirin mecamylamine da cytisine akan rage yawan amfani da sucrose na tsawon lokaci a cikin bincikenmu (awa 2 vs minti 30), wataƙila saboda yawan ƙananan sassan nAChR da mecamylamine da cytisine suka yi niyya idan aka kwatanta da waɗanda varenicline ya yi niyya [ 66 , 67 ]. Bugu da ƙari, bambancin pharmacokinetics na mecamylamine da cytisine idan aka kwatanta da varenicline, suma na iya taimakawa wajen wannan tasirin da aka lura. Duk da haka, waɗannan damar suna da hasashe kuma za a buƙaci a bincika su a cikin nazarin gaba. Haka kuma, za a iya kawar da tashin zuciya ko tasirin motsa jiki saboda alluran da aka yi amfani da su a cikin bincikenmu na varenicline (0.3–2 mg/kg), mecamylamine (0.5–2 mg/kg) da cytisine (2–4 mg/kg) sun yi kama da alluran da aka yi amfani da su a cikin binciken da ya gabata, wato varenicline (0.3–3 mg/kg), mecamylamine (0.5–4 mg/kg) da cytisine (0.3–5 mg/ kg ) [ 46-51 , 68-70 ].
Lura da cewa ba wai kawai magungunan varenicline da cytisine na ɓangare ba ne, har ma da magungunan mecamylamine na antagonist, rage yawan amfani da sucrose na iya ba da haske game da tsarin kwayoyin halitta inda magungunan β2* nAChR ke haifar da tasirinsu. Wata fassarar da za a iya fahimta ita ce yana ɗauke da rage tasirin nAChR. Kodayake an tabbatar da cewa magungunan acetylcholine da nAChR da farko suna haifar da kunna nAChR, wannan yana biyo baya da sauri ta hanyar gyare-gyaren kwayoyin halitta wanda ke haifar da rufewar tashoshi da toshewar mai karɓa ko rage tasirin [ 71-73 ] . An ba da shawarar cewa magungunan nicotine da nicotinic receptor suna yin tasirin halayensu gabaɗaya ta hanyar rage tasirin masu karɓar nicotinic don su zama tushen tsarin aikinsu, aƙalla a wani ɓangare, akan analgesia, ɓacin rai, daina shan taba da sauransu [ 74-76 ] . Idan masu agonists na nAChR suna yin tasirinsu mai amfani ta hanyar toshewar mai karɓar, masu antagonists na iya zama mafi amfani daga mahangar asibiti. A madadin haka, masu agonists na nAChR na ɓangare, kamar varenicline, na iya zama mafi tasiri ta hanyar magani.
A cikin wannan binciken, mun kuma gano cewa fallasa sucrose na dogon lokaci ya haifar da ƙaruwa a cikin α4β2* da raguwar masu karɓar α6β2* nAChR a cikin NAc. Abin sha'awa, gudanar da nicotine yana haifar da canje-canje makamancin haka a cikin matakan α4β2* da α6β2* nAChRs, kuma zuwa girman da aka samu a cikin wannan binciken tare da sucrose [77-79 ] . Kodayake har yanzu ba a fahimci hanyoyin da ke da alhakin hakan ba, an nuna cewa canje-canje a cikin α4β2* da α6β2* nAChRs suna ba da gudummawa ga sake aiwatar da nicotine da kuma sarrafa kai [ 80-84 ]. Dangane da kwatancen, canje -canjen da aka lura a cikin nAChRs tare da shan sucrose na iya zama tushen halayen jaraba na sucrose. Ya kamata a lura cewa a halin yanzu ba a san ko canje-canjen da aka lura a cikin matakan α4β2 * da α6β2* nAChRs sun faru ne saboda sauƙin sucrose ko kuma saboda ƙaruwar yawan abincin kalori. Duk da cewa varenicline yana da irin wannan tasiri akan amfani da saccharin da sucrose a cikin bincikenmu, yana nuna cewa rashin jin daɗi a matsayin shawara mai kyau, nazarin da za a yi nan gaba ya kamata ya cire ƙarin yawan kalori a matsayin abin da ke haifar da canje-canjen da aka lura a matakan bayyanar nAChR. Wannan kuma zai taimaka wajen fayyace hanyar da ke haifar da canje-canjen masu karɓar abinci da aka gabatar a cikin bincikenmu. Dangane da yawan sukari da kuma, gabaɗaya, yawan cin abinci, hasashe ya ci gaba da kasancewa game da halayen jaraba na waɗannan abincin. Hakika, wani bita na baya-bayan nan da Hebebrand da abokan aikinsa [ 85 ] suka yi ya gano bambanci tsakanin jarabar abinci da kuma sunan jarabar cin abinci da aka fi so. Duk da waɗannan hasashe, ɗabi'a da jijiyoyi suna da alaƙa da yawan shan sukari, suna sanya hanyar mesolimbic a matsayin manufa mai kyau don shiga tsakani na maganin magunguna.
A ƙarshe, tsangwama ta hanyar magunguna tare da nAChRs yana shafar amfani da amfani da lafiyar sucrose. Bugu da ƙari, dangane da daban-daban na nAChRs agonists da antagonists an gwada, mun yanke cewa β2 * nAChRs suna da hannu wajen daidaita tasirin magunguna akan yawan maye. Mun nuna cewa nasarar sucrose tana karuwa da α4β2 * da raguwa a cikin α6β2 * nAChRs a cikin NAc, suna ba da shawarar wannan yankin a matsayin ɗan takarar da zai iya kasancewa mai sassauci a cikin tsarin maye gurbin amfani. Studiesarin karatuttukan ingantattu ne ingantattu don inganta aikin ƙaddamar da NAc a cikin daidaita halayen cinye maye a matsayin aikin nAChRs. Aƙarshe, bincikenmu ya ba da shawarar dabarun magani na rayuwa game da rayuwa don rage yawan sukari.
Goyan bayan Bayanan
Doi: 10.1371 / journal.pone.0150270.s001
(DOCX)
Acknowledgments
Marubutan suna son yin godiya ga Carla Campus don kyakkyawan aikin fasaha a cikin waɗannan karatun.
Marubucin Mataimaki
Amincewa da kuma tsara gwaje-gwajen: MS SEB JH MM MQ. Yi gwaje-gwajen: MS MQ JH MM OLP VT AB. Binciken bayanan: MS MQ VT AB OLP. Abubuwan da aka ba da gudummawar reagents / kayan aiki / kayan aikin bincike: MS MQ SEB AB JH MM OLP. Rubuta takarda: MS MQ SEB MM AB JH OLP.
References
- 1. WHO. Kiba: hanawa da sarrafa annobar duniya. Rahoton wani tattaunawar WHO. Rahoton rahoton kungiyar Lafiya ta Duniya. 2000; 894: i-xii, 1 – 253. Epub 2001 / 03 / 10. 11234459.
<> 3. Rada P, Avena NM, Hoebel BG. Yawan binging a kan sukari akai-akai yana sakin dopamine a cikin harsashin accumbens. Neuroscience. 2005; 134 (3): 737–44. Epub 2005/07/01. Doi: 10.1016 / j.neuroscience.2005.04.043 pmid: 15987666.Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani Duba Mataki na ashirin da PubMed / NCBI Google masani 4. Bassareo V. Cucca F Binciken kwakwalwar hali. 2015; 294:215–23. doi: 10.1016/j.bbr.2015.08.006 pmid:26275926.5. Bassareo V. Cucca F Binciken kwakwalwar hali. 2015; 287:200–6. doi: 10.1016/j.bbr.2015.03.056 pmid:25827930.6. Bassareo V. Cucca F Jaridar Turai ta neuroscience. 2015; 41 (6): 802–9. doi: 10.1111/ejn.12839 pmid:25645148.7. De Vries TJ, Shippenberg TS. Tsarin jijiyoyi da ke ƙarƙashin jarabar opiate. Jaridar Neuroscience: Jaridar hukuma na Society for Neuroscience. 2002;22 (9): 3321–5.8. Di Chiara G, Imperato A. Magungunan da mutane ke cin zarafi sun fi son ƙara yawan ƙwayar synaptic dopamine a cikin tsarin mesolimbic na berayen masu motsi da yardar rai. Abubuwan da aka ɗauka na Cibiyar Nazarin Kimiyya ta Ƙasa ta Amurka ta Amurka. 1988;85 (14):5274–8. Epub 1988/07/01. pmid:2899326; PubMed Central PMCID: PMCPMC281732. doi: 10.1073/pnas.85.14.52749. Everitt BJ, Wolf ME. Psychomotor stimulant jaraba: hangen nesa tsarin jijiyoyi. Jaridar Neuroscience: Jaridar hukuma na Society for Neuroscience. 2002;22 (9): 3312–20.10. Hernandez L, Hoebel BG. Ladan abinci da hodar Iblis suna haɓaka dopamine na extracellular a cikin ƙwayoyin ƙwayoyin cuta kamar yadda aka auna ta microdialysis. Ilimin rayuwa. 1988;42 (18):1705–12. Saukewa: 3362036. doi: 10.1016/0024-3205(88)90036-711. Hurd YL. Jaridar neurochemistry. 1988;51 (4): 1314–6. Saukewa: 3418351. doi: 10.1111/j.1471-4159.1988.tb03103.x12. Picciotto MR, Corrigall WA. Tsarin jijiyoyi da ke da alaƙa da halayen nicotine: da'irori na jijiyoyi da ƙwayoyin ƙwayoyin cuta. Jaridar Neuroscience: Jaridar hukuma na Society for Neuroscience. 2002;22 (9): 3338–41. 20026360. pmid:11978809.13. Pothos E, Rada P, Mark GP, Hoebel BG. Dopamine microdialysis a cikin tsakiya accumbens a lokacin m da kuma na kullum morphine, naloxone-precipitated janye da clonidine magani. Binciken kwakwalwa. 1991;566 (1–2):348–50. Saukewa: 1814554. doi: 10.1016/0006-8993(91)91724-f14. Rada P, Pothos E, Mark GP, Hoebel BG. Shaidar microdialysis cewa acetylcholine a cikin ƙwayar ƙwayar cuta yana da hannu a cikin cirewar morphine da magani tare da clonidine. Binciken kwakwalwa. 1991;561 (2):354–6. Saukewa: 1802350. doi: 10.1016/0006-8993(91)91616-915. Colantuoni C, Schwenker J, McCarthy J, Rada P, Ladenheim B, Cadet JL, et al. Yawan cin sukari yana canza ɗaurin dopamine da masu karɓar mu-opioid a cikin kwakwalwa. Neuroreport. 2001;12 (16):3549–52. doi: 10.1097/00001756-200111160-0003516. Bello NT, Lucas LR, Hajnal A. Maimaita hanyar samun sucrose yana rinjayar dopamine D2 yawan mai karɓa a cikin striatum. Neuroreport. 2002;13 (12): 1575–8. pmid:12218708; PubMed Tsakiyar PMCID: PMC1945096. doi: 10.1097/00001756-200208270-0001717. Spangler R, Wittkowski KM, Goddard NL, Avena NM, Hoebel BG, Leibowitz SF. Illar opiate-kamar ciwon sukari akan maganganun kwayoyin halitta a wuraren lada na kwakwalwar bera. Binciken Kwakwalwa Binciken Kwakwalwar Kwakwalwa. 2004; 124 (2): 134–42. doi: 10.1016/j.molbrainres.2004.02.013 pmid: 15135221.18. Unterwald EM, Rubenfeld JM, Kreek MJ. Maimaita sarrafa cocaine yana haɓaka kappa da mu, amma ba delta, masu karɓar opioid ba. Neuroreport. 1994; 5 (13): 1613–6. Saukewa: 7819531. doi: 10.1097/00001756-199408150-0001819. Unterwald EM, Kreek MJ, Cuntapay M. Yawan yawan maganin cocaine yana haifar da sauye-sauye masu karɓa na cocaine. Binciken kwakwalwa. 2001;900 (1): 103–9. Saukewa: 11325352. doi: 10.1016/s0006-8993(01)02269-720. Alburges ME, Narang N, Wamsley JK. Canje-canje a cikin tsarin mai karɓa na dopaminergic bayan gudanarwar cocaine na yau da kullun. Synapse (New York, NY). 1993;14 (4):314–23. doi: 10.1002/syn.890140409 pmid:8161369.21. Moore RJ, Vinsant SL, Nader MA, Porrino LJ, Friedman DP. Tasirin sarrafa kansa na cocaine akan masu karɓar dopamine D2 a cikin birai rhesus. Synapse (New York, NY). 1998;30 (1):88–96. doi: 10.1002/(SICI)1098-2396(199809)30:1<88::AID-SYN11>3.0.CO;2-L pmid:9704885.22. Georges F, Stinus L, Bloch B, Le Moine C. Kwayoyin cututtuka na morphine na yau da kullum da kuma cirewa ba tare da bata lokaci ba suna hade da gyare-gyare na mai karɓa na dopamine da neuropeptide gene magana a cikin rat striatum. Jaridar Turai ta neuroscience. 1999;11 (2):481–90. Saukewa: 10051749. doi: 10.1046/j.1460-9568.1999.00462.x23. Turchan J, Lason W, Budziszewska B, Przewlocka B. Tasirin gudanarwar morphine guda ɗaya da maimaitawa akan prodynorphin, proenkephalin da dopamine D2 receptor gene magana a cikin kwakwalwar linzamin kwamfuta. Neuropeptides. 1997;31 (1):24–8. Saukewa: 9574833. doi: 10.1016/s0143-4179(97)90015-924. Spangler R, Goddard NL, Avena NM, Hoebel BG, Leibowitz SF. D3 dopamine mai karɓa mRNA a cikin dopaminergic da dopaminoceptive yankuna na kwakwalwar bera don amsawa ga morphine. Binciken Kwakwalwa Binciken Kwakwalwar Kwakwalwa. 2003;111 (1–2):74–83. Saukewa: 12654507. doi: 10.1016/s0169-328x(02)00671-x25. Uhl GR, Ryan JP, Schwartz JP. Morphine yana canza yanayin magana ta preproenkephalin. Binciken kwakwalwa. 1988;459 (2):391–7. Saukewa: 3179713. doi: 10.1016/0006-8993(88)90658-026. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ. Haɓaka ɗaurin mai karɓar mu opioid da PET ta gano a cikin maza masu dogaro da hodar iblis yana da alaƙa da sha'awar cocaine. Magungunan yanayi. 1996; 2 (11): 1225–9. Saukewa: 8898749. doi: 10.1038/nm1196-122527. Colantuoni C, Rada P, McCarthy J, Patten C, Avena NM, Chadeayne A, et al. Shaida cewa tsaka-tsaki, yawan cin sukari yana haifar da dogaron opioid na ƙarshe. Binciken Kiba. 2002; 10 (6): 478-88. Epub 2002/06/11. doi: 10.1038/oby.2002.66 pmid:12055324.28. Rada PV, Mark GP, Taylor KM, Hoebel BG. Morphine da naloxone, ip ko na gida, suna shafar acetylcholine na waje a cikin accumbens da prefrontal cortex. Pharmacology, biochemistry, da hali. 1996;53 (4):809–16. Saukewa: 8801582. doi: 10.1016/0091-3057(95)02078-029. Rada P, Jensen K, Hoebel BG. Tasirin janyewar nicotine da mecamylamine akan extracellular dopamine da acetylcholine a cikin ƙwayoyin bera accumbens. Psychopharmacology. 2001; 157 (1): 105–10. Saukewa: 11512050. doi: 10.1007/s00213010078130. Rada P, Johnson DF, Lewis MJ, Hoebel BG. A cikin berayen da aka yi amfani da barasa, naloxone yana rage dopamine na extracellular kuma yana haɓaka acetylcholine a cikin ƙwayar ƙwayar cuta: shaidar janyewar opioid. Pharmacology, biochemistry, da hali. 2004;79 (4):599–605. doi: 10.1016/j.pbb.2004.09.011 pmid:15582668.31. Berridge KC. Daga kuskuren tsinkaya zuwa salience mai ban sha'awa: ƙididdigar mesolimbic na kwarin gwiwa. Jaridar Turai ta neuroscience. 2012;35 (7): 1124–43. Epub 2012/04/11. doi: 10.1111/j.1460-9568.2012.07990.x pmid:22487042; PubMed Tsakiyar PMCID: PMCPMC3325516.32. Tindell AJ, Berridge KC, Zhang J, Pecina S, Aldridge JW. Ventral pallidal neurons code ƙarfafa ƙarfafawa: haɓakawa ta hanyar fahimtar mesolimbic da amphetamine. Jaridar Turai ta neuroscience. 2005;22 (10):2617–34. Epub 2005/11/26. doi: 10.1111/j.1460-9568.2005.04411.x pmid:16307604.33. Wyvell CL, Berridge KC. Intra-accumbens amphetamine yana haɓaka ingantaccen sharadi na lada na nasara: haɓaka lada "so" ba tare da haɓaka "son" ko ƙarfafa amsa ba. Jaridar Neuroscience: Jaridar hukuma na Society for Neuroscience. 2000;20 (21):8122–30. Epub 2000/10/26. Saukewa: 11050134.34. Wyvell CL, Berridge KC. Haɓaka haɓaka ta hanyar bayyanar amphetamine da ta gabata: ƙara yawan abin da ke haifar da “so” don ladan nasara. Jaridar Neuroscience: Jaridar hukuma na Society for Neuroscience. 2001;21 (19):7831–40. Epub 2001/09/22. Saukewa: 11567074.35. Kenny PJ. Hannun salon salula na yau da kullun da kwayoyin halitta a cikin kiba da jarabar ƙwayoyi. Nature reviews Neuroscience. 2011;12 (11):638–51. Epub 2011/10/21. doi: 10.1038/nrn3105 pmid:22011680.36. Avena NM, Rada P, Hoebel BG. Shaida don jarabar sukari: halayya da tasirin neurochemical na tsaka-tsaki, yawan cin sukari. Neuroscience da biobehavioral reviews. 2008;32 (1):20–39. Epub 2007/07/10. doi: 10.1016/j.neubiorev.2007.04.019 pmid:17617461; PubMed Tsakiyar PMCID: PMCPMC2235907.37. Mark GP, Shabani S, Dobbs LK, Hansen ST. Cholinergic modulation na mesolimbic dopamine aiki da lada. Physiology & hali. 2011; 104 (1): 76–81. Epub 2011/05/10. doi: 10.1016/j.physbeh.2011.04.052 pmid:21549724.38. McCallum SE, Taraschenko OD, Hathaway ER, Vincent MY, Glick SD. Tasirin 18-methoxycoronaridine akan ghrelin-induced yana ƙaruwa a cikin cin sucrose da tarin dopamine a cikin berayen mata. Psychopharmacology. 2011;215 (2):247–56. Epub 2011/01/07. doi: 10.1007/s00213-010-2132-0 pmid:21210086; PubMed Tsakiyar PMCID: PMCPMC3790315.39. Grady SR, Drenan RM, Breining SR, Yohannes D, Wageman CR, Fedorov NB, et al. Bambance-bambancen tsari yana ƙayyade zaɓin dangi na mahaɗan nicotinic don alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- da alpha 7-nicotine acetylcholine masu karɓa. Neuropharmacology. 2010;58 (7):1054–66. Epub 2010/02/02. doi: 10.1016/j.neuropharm.2010.01.013 pmid:20114055; PubMed Tsakiyar PMCID: PMCPMC2849849.40. Mihalak KB, Carroll FI, Luetje CW. Varenicline wani bangare ne na agonist a alpha4beta2 kuma cikakken agonist a alpha7 neuronal nicotinic receptors. Ilimin kimiyyar kwayoyin halitta. 2006;70 (3):801–5. Epub 2006/06/13. doi: 10.1124/mol.106.025130 pmid: 16766716.41. Garrison GD, Dugan SE. Varenicline: zaɓin jiyya na farko don daina shan taba. Clinical therapeutics. 2009;31 (3):463–91. Epub 2009/04/28. doi: 10.1016/j.clinthera.2009.03.021 pmid:19393839.42. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, alpha4beta2 nicotinic acetylcholine mai karɓar agonist mai karɓa, zaɓi yana rage yawan amfani da ethanol da nema. Abubuwan da aka ɗauka na Cibiyar Nazarin Kimiyya ta Ƙasa ta Amurka ta Amurka. 2007;104 (30):12518–23. Epub 2007/07/13. doi: 10.1073/pnas.0705368104 pmid:17626178; PubMed Central PMCID: PMCPMC1914040.43. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. Bayanan ilimin harhada magunguna na alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, ingantaccen taimako na daina shan taba. Neuropharmacology. 2007;52 (3): 985–94. Epub 2006/12/13. doi: 10.1016/j.neuropharm.2006.10.016 pmid:17157884.44. Rollema H, Shrikhande A, Ward KM, Tingley FD 3rd, Coe JW, O'Neill BT, et al. Pre-clinical Properties na alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine da dionicline suna fassara zuwa ingancin asibiti don dogaro da nicotine. Mujallar Burtaniya na Magunguna. 2010; 160 (2): 334-45. Epub 2010/03/25. doi: 10.1111/j.1476-5381.2010.00682.x pmid:20331614; PubMed Tsakiyar PMCID: PMCPMC2874855.{C}{C}{C}45. Mai hikima RA. Shan ethanol na son rai a cikin berayen bayan fallasa ga ethanol akan jadawali daban-daban. Psychopharmacologia. 1973;29 (3):203–10. Epub 1973/01/01. Saukewa: 4702273. doi: 10.1007/bf00414034{C}{C}{C}46. Crunelle CL, Schulz S, de Bruin K, Miller ML. Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Turai. 2;3 (2011):21–2. doi: 205/j.euroneuro.10 pmid:10.1016.{C}{C}{C}47. Biala G, Staniak N, Budzynska B. Tasirin varenicline da mecamylamine akan saye, magana, da sake dawo da fifikon wuri na nicotine ta hanyar priming na miyagun ƙwayoyi a cikin berayen. Naunyn-Schmiedeberg's Archives of Pharmacology. 2010;381(4):361–70. doi: 10.1007/s00210-010-0498-5 na yamma:20217050.48. Levin ED, Mead T, Rezvani AH, Rose JE, Gallivan C, Gross R. Mai adawa da nicotinic mecamylamine ya fi dacewa ya hana cocaine vs. cin abinci na kai a cikin berayen. Physiology & hali. 2000;71 (5):565–70. Saukewa: 11239676. doi: 10.1016/s0031-9384(00)00382-649. Liu X, Caggiula AR, Yee SK, Nobuta H, Poland RE, Pechnick RN. Sake dawo da dabi'ar neman nicotine ta hanyar abubuwan motsa jiki masu alaƙa da ƙwayoyi bayan bacewar beraye. Psychopharmacology. 2006;184 (3–4):417–25. doi: 10.1007/s00213-005-0134-0 pmid:16163522; PubMed Tsakiyar PMCID: PMC2810478.50. Tutka P, Zatonski W. Cytisine don maganin ƙwayar nicotine: daga kwayar halitta zuwa tasirin warkewa. Rahoton Pharmacological: PR. 2006;58 (6):777–98. Epub 2007/01/16. Saukewa: 17220536.51. Tutka P, Mroz T, Bednarski J, Styk A, Ognik J, Mosiewicz J, et al. Cytisine yana hana aikin anticonvulsant na phenytoin da lamotrigine a cikin mice. Rahoton Pharmacological: PR. 2013; 65 (1): 195-200. Saukewa: 23563038. doi: 10.1016/s1734-1140(13)70978-252. Quik M, Polonskaya Y, Gillespie A, KL G, Langston JW. Canje-canje daban-daban a cikin nicotinic receptor alpha6 da beta3 subunit messenger RNAs a cikin abubuwan birai na nigra bayan lalatawar nigrostriatal. Kimiyyar Jijiya. 2000; 100 (1): 63-72. Epub 2000/09/21. Saukewa: 10996459. doi: 10.1016/s0306-4522(00)00244-x53. Quik M, Polonskaya Y, Kulak JM, McIntosh JM. Rashin lahani na wuraren ɗaure 125I-alpha-conotoxin MII zuwa lalacewar nigrostriatal a biri. Jaridar Neuroscience: Jaridar hukuma na Society for Neuroscience. 2001;21 (15): 5494-500. Epub 2001/07/24. shafi: 11466420.54. Simms JA, Steensland P, Medina B, Abernathy KE, Chandler LJ, Wise R, et al. Samun dama ga 20% ethanol yana haifar da yawan amfani da ethanol a cikin Long-Evans da berayen Wistar. Alcoholism, bincike na asibiti da gwaji. 2008;32 (10): 1816–23. Epub 2008/08/02. doi: 10.1111/j.1530-0277.2008.00753.x pmid:18671810; PubMed Tsakiyar PMCID: PMCPMC3151464.55. Quik M, Wonnacott S. {alpha}6{beta}2* da {alpha}4{beta}2* Masu karɓar Nicotinic Acetylcholine A Matsayin Manufofin Magunguna don Cutar Parkinson. Pharmacol Rev. 2011;63(4):938–66. doi: 10.1124/pr.110.003269{C}{C}{C}56. Feduccia AA, Simms JA, Mill D, Yi HY, Bartlett SE. Varenicline yana rage yawan shan ethanol kuma yana haɓaka sakin dopamine ta hanyar neuronal nicotinic acetylcholine receptors a cikin ƙwayar ƙwayar cuta. Mujallar Burtaniya na Magunguna. 2014. Epub 2014/03/19. doi: 10.1111/bph.12690 pmid:24628360.{C}{C}{C}57. Mark GP, Rada P, Pothos E, Hoebel BG. Tasirin ciyarwa da sha akan sakin acetylcholine a cikin mahaifa accumbens, striatum, da hippocampus na berayen da ke nuna halin walwala. Jaridar neurochemistry. 1992;58 (6):2269–74. Epub 1992/06/01. Saukewa: 1573406. doi: 10.1111/j.1471-4159.1992.tb10973.x{C}{C}{C}58. Avena NM, Rada P, Moise N, Hoebel BG. Sucrose sham ciyarwa akan jadawalin binge yana sakin dopamine akai-akai kuma yana kawar da amsawar satiety acetylcholine. Kimiyyar Jijiya. 2006;139 (3):813–20. Epub 2006/02/08. doi: 10.1016/j.neuroscience.2005.12.037 pmid:16460879.{C}{C}{C}59. Hoebel BG, Avena NM, Rada P. Accumbens dopamine-acetylcholine ma'auni a cikin kusanci da kaucewa. Ra'ayi na yanzu a cikin ilimin harhada magunguna. 2007; 7 (6): 617–27. doi: 10.1016/j.coph.2007.10.014{C}{C}{C}60. Aosaki T, Miura M, Suzuki T, Nishimura K, Masuda M. Acetylcholine-dopamine balance hypothesis a cikin striatum: sabuntawa. Geriatrics & Gerontology International. 2010;10 Gabatarwa 1:S148–57. Epub 2010/07/16. doi: 10.1111/j.1447-0594.2010.00588.x pmid:20590830.{C}{C}{C}61. Ostlund SB, Kosheleff AR, Maidment NT. Bambance-bambancen tasirin toshewar mai karɓar tsarin cholinergic akan yunƙuri na Pavlovian da zaɓin aikin da aka jagoranta. Neuropsychopharmacology: bugu na hukuma na Kwalejin Amurka na Neuropsychopharmacology. 2014;39 (6): 1490–7. Epub 2013/12/29. doi: 10.1038/npp.2013.348 pmid:24370780; PubMed Tsakiyar PMCID: PMCPMC3988553.{C}{C}{C}62. Ford MM, Fretwell AM, Nickel JD, Mark GP, Strong MN, Yoneyama N, et al. Tasirin mecamylamine akan ethanol da sarrafa kai na sucrose. Neuropharmacology. 2009;57 (3):250–8. Epub 2009/06/09. doi: 10.1016/j.neuropharm.2009.05.012 pmid: 19501109; PubMed Tsakiyar PMCID: PMCPMC2716427.{C}{C}{C}63. Palotai M, Bagosi Z, Jaszberenyi M, Csabafi K, Dochnal R, Manczinger M, et al. Ghrelin yana haɓaka sakin dopamine da ke haifar da nicotine a cikin bera striatum. Neurochemistry International. 2013;63 (4):239–43. doi: 10.1016/j.neuint.2013.06.014 pmid:23831084.{C}{C}{C}64. Sajja RK, Rahman S. Lobeline da cytisine suna rage halayen shan ethanol na son rai a cikin mice C57BL / 6J namiji. Ci gaba a cikin neuro-psychopharmacology & ilimin halin kwakwalwa. 2011;35 (1):257–64. Epub 2010/11/30. doi: 10.1016/j.pnpbp.2010.11.020 pmid:21111768.{C}{C}{C}65. Shaffer CL, Gunduz M, Ryder TF, O'Connell TN. Bambance-bambancen nau'o'in halittu a cikin biotransformation na alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist: tasirin keɓaɓɓen metabolites na glucuronide akan yanayin fili gabaɗaya. Drug metabolism da disposition: nazarin halittu rabo na sunadarai. 2010;38 (2):292–301. Epub 2009/11/17. doi: 10.1124/dmd.109.030171 pmid: 19910512.66. Nickell JR, Grinevich VP, Siripurapu KB, Smith AM, Dwoskin LP. Yiwuwar amfanin warkewa na mecamylamine da stereoisomers. Pharmacology, biochemistry, da hali. 2013; 108:28–43. Epub 2013/04/23. doi: 10.1016/j.pbb.2013.04.005 pmid:23603417; PubMed Tsakiyar PMCID: PMCPMC3690754.67. Rahman S, Engleman EA, Bell RL. Motsin mai karɓa na Nicotinic don magance barasa da dogaro da ƙwayoyi. Frontiers a neuroscience. 2014; 8:426. Epub 2015/02/03. doi: 10.3389/fnins.2014.00426 pmid:25642160; PubMed Tsakiyar PMCID: PMCPMC4295535.68. Zaniewska M, McCreary AC, Stefanski R, Przegalinski E, Filip M. Tasirin varenicline akan martani mai tsanani da maimaita locomotor ga nicotine a cikin berayen. Synapse (New York, NY). 2008;62 (12):935–9. doi: 10.1002/syn.20564 pmid:18798299.69. Goutier W, Kloeze MB, McCreary AC. Tasirin varenicline akan haɓakawa da bayyana halayen halayen nicotine da ke haifar da haɓakawa a cikin berayen. ilmin halitta jaraba. 2015;20 (2):248–58. doi: 10.1111/adb.12108 pmid:24251901.70. Igari M, Alexander JC, Ji Y, Qi X, Papke RL, Bruijnzeel AW. Varenicline da cytisine suna rage dysphoric-kamar jihar da ke da alaƙa da cirewar nicotine ba tare da bata lokaci ba a cikin berayen. Neuropsychopharmacology: bugu na hukuma na Kwalejin Amurka na Neuropsychopharmacology. 2014;39 (2):455–65. doi: 10.1038/npp.2013.216 pmid:23966067; PubMed Tsakiyar PMCID: PMC3870769.71. McCarthy MJ, Zhang H, Neff NH, Hadjiconstantinou M. Desensitization na delta-opioid receptors a cikin tsakiya accumbens a lokacin janye nicotine. Psychopharmacology (Berl). 2011; 213 (4): 735–44. Epub 2010/10/14. doi: 10.1007/s00213-010-2028-z pmid:20941594.72. Buccafusco JJ, Beach JW, Terry AV. Rashin hankali na nicotinic acetylcholine receptors a matsayin dabarun ci gaban ƙwayoyi. J Pharmacol Exp Ther. 2009;328 (2):364–70. Saukewa: 19023041. doi: 10.1124/jpt.108.145292.73. Picciotto MR, Addy NA, Mineur YS, Brunzell DH. Ba "ko dai / ko" ba: Kunnawa da rashin jin daɗi na masu karɓar nicotinic acetylcholine duka suna ba da gudummawa ga halaye masu alaƙa da jarabar nicotine da yanayi. Prog Neurobiol. 2008; 84:329–42. Saukewa: 18242816. doi: 10.1016/j.pneurobio.2007.12.005.74. Ortells MO, Arias HR. Cibiyoyin Neuronal na jarabar nicotine. Int J Biochem Cell Biol. 2010; 42 (12): 1931–5. Epub 2010/09/14. S1357-2725(10)00301-8 [pii] doi: 10.1016/j.biocel.2010.08.019 pmid:20833261.75. Zhang J, Xiao YD, Jordan KG, Hammond PS, Van Dyke KM, Mazurov AA, et al. Tasirin analgesic da aka yi sulhu ta hanyar neuronal nicotinic acetylcholine agonists mai karɓa: daidaitawa tare da rashin jin daɗi na masu karɓar alpha4beta2*. Eur J Pharm Sci. 2012;47 (5):813–23. Epub 2012/10/06. S0928-0987(12)00366-1 [pii] doi: 10.1016/j.ejps.2012.09.014 pmid:23036283.76. Mineur YS, Picciotto MR. Masu karɓa na Nicotine da Bacin rai: sake dubawa da sake duba hasashen cholinergic. Trends Pharmacol Sci. 2010; 31:580–6. Epub 2010/10/23. S0165-6147(10)00167-7 [pii] doi: 10.1016/j.tips.2010.09.004 pmid:20965579.77. Renda A, Nashmi R. Maganin ciwon nicotine na yau da kullum ya isa ya daidaita alpha4 * masu karɓa na nicotinic da kuma ƙara yawan ƙwayar nicotine na baki a cikin mice. BMC neuroscience. 2014; 15:89. Epub 2014/07/21. doi: 10.1186/1471-2202-15-89 pmid:25038610; PubMed Tsakiyar PMCID: PMCPMC4133059.78. Exley R, Clements MA, Hartung H, McIntosh JM, Franklin M, Bermudez I, et al. An rage watsawar kwayar cutar dopamine bayan nicotine na yau da kullun tare da raguwa a cikin sarrafa mai karɓar alpha6-nicotinic a cikin ƙwayoyin ƙwayoyin cuta. Jaridar Turai ta neuroscience. 2013;38 (7): 3036–43. Epub 2013/07/12. doi: 10.1111/ejn.12298 pmid:23841846.79. Perez XA, McIntosh JM, Quik M. Jiyya na nicotine na dogon lokaci yana daidaita alpha6beta2 * magana mai karɓa na nicotinic da aiki a cikin ƙananan ƙwayoyin cuta. Jaridar neurochemistry. 2013;127 (6):762–71. Epub 2013/09/03. doi: 10.1111/jnc.12442 pmid:23992036; PubMed Tsakiyar PMCID: PMCPMC3859710.80. Madsen HB, Koghar HS, Pooters T, Massalas JS, Drago J, Lawrence AJ. Matsayin alpha4- da alpha6-mai ɗauke da masu karɓar nicotinic a cikin saye da kula da sarrafa kan nicotine. Adadin Biol. 2014. Epub 2014/04/23. doi: 10.1111/adb.12148 pmid:24750355.81. Picciotto MR, Kenny PJ. Hanyoyin kwayoyin halitta masu alaƙa da halayen nicotine. Cold Spring Harb Perspect Med. 2013; 3 (1): a012112. Epub 2012/11/13. cshperspect.a012112 [pii] doi: 10.1101/cshperspect.a012112 pmid:23143843; PubMed Tsakiyar PMCID: PMC3530035.82. Leslie FM, Mojica CY, Reynaga DD. Masu karɓar Nicotinic a cikin hanyoyin jaraba. Mol Pharmacol. 2013;83 (4):753–8. Epub 2012/12/19. mol.112.083659 [pii] doi: 10.1124/mol.112.083659 pmid:23247824.83. De Biasi M, Dani JA. Sakamako, jaraba, janyewa ga nicotine. Annu Rev Neurosci. 2011; 34:105–30. Epub 2011/03/29. doi: 10.1146/annurev-neuro-061010-113734 pmid:21438686; PubMed Tsakiyar PMCID: PMC3137256.84. Quik M, Perez XA, Grady SR. Matsayin alpha6 masu karɓar nicotinic a cikin aikin dopaminergic na CNS: dacewa da jaraba da cututtukan jijiyoyin jini. Biochem Pharmacol. 2011;82 (8):873–82. Epub 2011/06/21. S0006-2952(11)00366-2 [pii] doi: 10.1016/j.bcp.2011.06.001 pmid:21684266; PubMed Tsakiyar PMCID: PMC3264546.85. Hebebrand J, Albayrak O, Adan R, Antel J, Dieguez C, de Jong J, et al. "Cin jaraba", maimakon "jarabar abinci", mafi kyawun kama dabi'ar jaraba-kamar cin abinci. Neuroscience da biobehavioral reviews. 2014; 47:295–306. doi: 10.1016/j.neubiorev.2014.08.016 pmid:25205078.
- 2. Te Morenga L, Mallard S, Mann J. Abincin abinci mai narkewa da nauyin jiki: sake duba tsari da kuma ƙididdigar meta na gwaji da gwaji na ƙungiyar. BMJ (Clinical bincike ed). 2013; 346: e7492. Epub 2013 / 01 / 17. doi: 10.1136 / bmj.e7492 pmid: 23321486.